Laquinimod Prospects Seen Small After RRMS CONCERTO Trial Failure

 
• By Sten Stovall

Teva has no current plans to further pursue laquinimod in relapsing-remitting multiple sclerosis after the investigational asset, developed by Sweden's Active Biotech, failed in the CONCERTO Phase III trial.

Disabled athlete
Laquinimod Suffers Another MS Setback

More from Clinical Trials

More from R&D